| Literature DB >> 26733552 |
James L Mohler1, Andrew J Armstrong2, Robert R Bahnson3, Anthony Victor D'Amico4, Brian J Davis5, James A Eastham6, Charles A Enke7, Thomas A Farrington8, Celestia S Higano9, Eric M Horwitz10, Michael Hurwitz11, Christopher J Kane12, Mark H Kawachi13, Michael Kuettel1, Richard J Lee14, Joshua J Meeks15, David F Penson16, Elizabeth R Plimack17, Julio M Pow-Sang18, David Raben19, Sylvia Richey20, Mack Roach21, Stan Rosenfeld22, Edward Schaeffer23, Ted A Skolarus20, Eric J Small24, Guru Sonpavde25, Sandy Srinivas26, Seth A Strope26, Jonathan Tward27, Dorothy A Shead28, Deborah A Freedman-Cass28.
Abstract
The NCCN Guidelines for Prostate Cancer address staging and risk assessment after an initial diagnosis of prostate cancer and management options for localized, regional, and metastatic disease. Recommendations for disease monitoring, treatment of recurrent disease, and systemic therapy for metastatic castration-recurrent prostate cancer also are included. This article summarizes the NCCN Prostate Cancer Panel's most significant discussions for the 2016 update of the guidelines, which include refinement of risk stratification methods and new options for the treatment of men with high-risk and very-high-risk disease and progressive castration-naïve disease.Entities:
Mesh：
Year: 2016 PMID： 26733552 DOI： 10.6004/jnccn.2016.0004
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908